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Abstract
Background: The association between baseline drug resistance mutations and subsequent increase in viral failure has
not been established for HIV-infected children. We evaluated drug resistance mutations at 39 codon sites (21 protease
inhibitor (PI) resistant codons and 18 nucleoside reverse transcriptase inhibitor (NRTI) resistant codons) for 92 clinically
stable NRTI-experienced, PI-naive HIV-infected children 2 to 17 years of age who were initiating new therapy with
ritonavir plus zidovudine (ZDV) and lamivudine or plus stavudine. The association between baseline drug resistance
mutations and subsequent viral failure after 12 and 24 weeks of highly active antiretroviral therapy (HAART) was studied.
Results: There were few primary PI associated mutations in this PI-naïve population, but 84% had NRTI mutations –
codons 215 (66%), 41 (42%), 67 (37%), 210 (33%) and 70 (32%). None of the specific baseline drug resistance mutations
were associated with a higher rate of virologic failure after 12 or 24 weeks of HAART. Median week 12 viral load
decreased as the total number of NRTI mutations at baseline increased (P = 0.006). Specifically, a higher level of baseline
ZDV resistance mutation was associated with a decrease in viral failure after 12 weeks on a ZDV-containing HAART
regimen (P = 0.017).
Conclusion: No increase was seen in the rate of viral failure after HAART associated with the presence of resistance
mutations at baseline. This paradoxical result may be due to adherence, replicative capacity, or ZDV hypersusceptibility
to the new regimen.
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Nucleoside reverse transcriptase inhibitors (NRTI) were
the first antiretroviral drugs available and continue to be
a component of anti-retroviral therapy (ART), despite the
emergence of drug resistance over time. Few studies have
investigated the role of pre-existing drug resistance and
response to therapy in children [1-4] compared to similar
studies in adults [5,6]. The largest published drug resist-
ance study of HIV-infected children found a high rate of
primary mutations associated with resistance to zidovu-
dine (ZDV), didanosine (ddI) and zalcitabine (ddC), but
concluded that none of the baseline drug mutations were
associated with a higher rate of virologic failure [2]. It is
possible that HIV drug resistance may evolve differently in
children because of differences in pharmacokinetics in
children, fewer drug options, and higher viral burden,
especially in younger children [7,8] and unique chal-
lenges to therapy compliance. Pediatric AIDS Clinical Tri-
als Group (PACTG) 338 was one of the first clinical trials
to evaluate highly active anti-retroviral therapy (HAART)
which included a protease inhibitor, ritonavir (RTV), in
children [9]. We investigated the role of baseline HIV drug
resistance mutations and response to therapy.
Results
There were very few primary resistance mutations to PIs in
this PI-naïve population, although 88% of the children
had polymorphisms that included secondary minor resist-
ance mutations. The most frequent secondary PI muta-
tions were at codons 63 (78%), 77 (37%), 36 (17%) and
10 (12%) (data not shown). Only two children had a pri-
mary PI resistance mutation (V82A). Other PI mutations
(71, 33 and 20) were present in less than 10% of the study
subjects. The most common NRTI mutations occurred at
codons 215 (66%), 41 (42%), 67 (37%), 210 (33%), 70
(32%), 69 (22%), 118 (21%) and 219 (21%). The
median numbers of baseline NRTI, thymidine analog
mutations (TAM), PI and total mutations were 3, 3, 2 and
4.5, respectively (both primary and secondary mutations
were included in the analysis for the PI mutations).
After 12 weeks on study, 51 (55%) subjects had viral loads
suppressed below 400 copies/ml. The number of subjects
with viral suppression dropped to 31 (34%) and 29
(32%) at weeks 24 and 48, respectively.
The association between the presence of a specific base-
line mutation and virologic failure after 12 weeks of
HAART was studied (Table 1). There was the suggestion of
a potential association with virologic failure for only one
baseline mutation, the NRTI codon 215 (unadjusted P =
0.019) for the three-drug combination regimen. However,
in this case the presence of resistance mutations was asso-
ciated with a decreased (rather than an increased) rate of
viral failure at week 12.
When the association between the number of baseline
resistance mutations and virologic failure after 12 weeks
of HAART was investigated, the only significant relation-
ship observed was in the ZDV/lamivudine (3TC)/RTV
combination regimen. A higher median number of NRTI
mutations at baseline was associated with virologic sup-
pression (1.5 versus 4.0, P = 0.016). There was no appar-
ent association between the number of baseline PI
resistance mutations and the level of viral load after 12
weeks of HAART, although as the number of baseline
NRTI mutations increased the level of viral load at week
12 decreased (Figure 1). A linear regression with adjust-
ment for censoring of viral loads at the detection limit
showed that after 12 weeks on HAART there was a
decrease of 0.245 in log10 RNA (copies/mL) associated
with each additional NRTI resistance mutation (P =
0.006).
Association between the level of baseline ZDV resistance
mutations and viral failure after 12 weeks on HAART was
investigated (Table 2). The level of baseline ZDV resist-
ance was categorized as i) high level (NRTI codon 215), ii)
intermediate level (at least one of the NRTI codons 41 or
210, but no high level mutation), iii) low level (at least
one of the NRTI codons 67, 70 or 219, but no high or
intermediate level mutation), or iv) no ZDV resistance
according to an algorithm specified prior to any data anal-
ysis. There was no association between baseline ZDV
resistance levels and viral failure after 12 weeks on HAART
for the two-drug HAART arm, although for the ZDV-con-
taining three-drug arm a higher level of baseline ZDV
resistance was associated with a lower chance of viral fail-
ure (P = 0.017). From Table 2 it should be noted that
whenever a codon 41 or 210 mutation was observed a
codon 215 mutation was also observed and the case was
classified as having a high level of resistance. Thus the
association between a high level of resistance and a lower
chance of viral failure should not be ascribed to only the
occurrence of a codon 215 mutation, but rather to the
occurrence of codon 215, 41 and/or 210 mutations.
The association between the presence of a specific base-
line mutation and virologic suppression during the first
24 weeks on HAART was explored. Viral response was cat-
egorized into three ordered levels: full suppression (viral
load no more than 400 copies/mL at week 12 or 24), par-
tial suppression (viral load dropped 0.75 log10 copies/mL
or more at week 12 or 24 from baseline, but no full sup-
pression), and no suppression. According to this defini-
tion, 56 (60%) subjects achieved full viral suppression
and an additional 13 (14%) achieved partial viral sup-
pression during the first 24 weeks on HAART. There was
no statistically significant (at the unadjusted 5% level)
association between any baseline mutation and virologic
suppression during the first 24 weeks on HAART.Page 2 of 8
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defined above, the association between the presence of a
specific baseline mutation and viral rebound between the
suppression and week 48 was evaluated. A rebound was
declared if there was an increase in RNA of more than one
log10 at any time between the time of suppression and
week 48 from the nadir viral load value at or before the
time of suppression, or if the child came off the assigned
protocol treatment at or before week 48. Of the 69 chil-
dren who achieved full or partial virologic suppression
during the first 24 weeks on HAART, 37 (54%) had a viral
rebound. In the three-drug arm children with mutation at
the NRTI codon 67 seemed to be less likely to have a viral
rebound after virologic suppression (unadjusted P =
0.002). There was also the suggestion of a potential asso-
ciation with virologic failure for the presence of any PI
mutation (unadjusted P = 0.020) in the three-drug arm
and for mutation at the NRTI codon 69 (unadjusted P =
0.028) in the two-drug arm, but these findings need to be
treated cautiously due to the problem of multiple compar-
isons (see statistical analysis section).
Discussion
We evaluated the association between resistance muta-
tions and their potential effect on the ability of antiviral
medications to reduce the viral burden in children with
HIV disease. As expected, there was little PI resistance and
considerable NRTI resistance in this PI-naïve, NRTI-expe-
rienced population. However, contrary to our expecta-
tions, we did not find an increase in the rate of viral failure
after HAART associated with the presence of resistance
mutations at baseline. The two specific associations iden-
tified at week 12 in our study (Table 1) were of borderline
significance and were in the direction of a decrease, rather
than an increase, in the rate of viral failure. As the number
of NRTI mutations at baseline increased, the median viral
load at week 12 decreased (P = 0.006) and as the baseline
level of ZDV resistance increased viral failure decreased
after 12 weeks on a ZDV-containing HAART regimen (P =
0.017). Our results were consistent with the drug resist-
ance study of 135 HIV-1 infected children by Eschleman
et al. [2]. Neither study produced significant evidence
linking a specific baseline drug resistance mutation to a
subsequent increase in viral failure. These results suggest
that baseline genotyping may not be necessary prior to
switching to a PI based regimen. This finding has particu-
lar pertinence in resource limited settings.
Possible explanations for these observations include
adherence, replicative capacity, and hypersusceptibility to
NRTIs. It is likely that children who were adherent to a
non-suppressive NRTI regimen and thus developed resist-
ance, were more likely to be adherent to a HAART regimen
that contained a brand new class of drugs. Friedland and
Williams [10] have suggested that the relationship
between the development of resistance and adherence to
the drugs is bell-shaped, such that both high and low
degrees of adherence decrease the likelihood of the devel-
opment of resistance. This concept has been supported by
several recent studies [11-13]. The RNA results from
Table 1: Association of baseline NTRI resistance mutations and viral failure after 12 weeks on HAART
d4T plus RTV group
Number with a mutation
ZDV plus 3TC plus RTV group
Number with a mutation
Baseline resistance 
mutation codons
RNA > 400 at week 12
(N = 19)
RNA ≤ 400 at week 12
(N = 26)
RNA > 400 at week 12
(N = 22)
RNA ≤ 400 at week 12
(N = 25)
Total number (%) with a 
resistance mutation at baseline
(N = 92 children)
NRTI resistance mutationsa
215 14 19 9b 19b 61 (66)
41 8 11 6 14 39 (42)
67 4 13 6 11 34 (37)
210 4 12 4 10 30 (33)
70 4 10 6 9 29 (32)
69 4 4 5 7 20 (22)
118 2 7 5 5 19 (21)
219 3 8 3 5 19 (21)
74 2 6 1 4 13 (14)
184 2 1 1 1 5 (5)
44 0 2 0 2 4 (4)
151 0 0 0 2 2 (2)
65 0 1 0 0 1 (1)
75 0 1 0 0 1 (1)
116 0 0 0 1 1 (1)
Any NRTI 16 23 15 23 77 (84)
Any PI or NRTI 19 25 21 25 90 (98)
a. No cases with mutations were observed for the following NRTI mutations: 62, 77 and 115.
b. P = 0.019, Fisher's exact testPage 3 of 8
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high viral loads at baseline, suggest that the drug(s) they
were taking were less effective in suppressing viral replica-
tion, resulting in ongoing viral production in the presence
of ART. Thus, children who were more adherent may have
been more likely to develop resistance to their non-sup-
pressive initial therapy regimens The children's viral loads
rapidly became undetectable once they were placed on
drugs that were more suppressive and to which they had
no baseline resistance (RTV and 3TC). Only 5 of the chil-
dren had the M184V and only 2 had the V82A mutations
at baseline. The effect would be less striking in children in
the two drug regimen since the mutations associated with
stavudine (d4T) resistance are primarily those seen with
ZDV, ddI and ddC to which the children had been previ-
ously exposed (codons 41, 67, 70, 210, 215, and 219).
Another explanation for these results might be reduced
replication capacity of the virus found in the children at
baseline. The NRTI mutations typically associated with
reduced fitness are M184V [14] and K65R [15]; however,
only 1 child had the K65R mutation and only 5 had the
M184V mutation at baseline. In addition, viral loads at
baseline were relatively high: the median baseline viral
load was 20,500 copies/mL and 20% of the children had
baseline viral loads of 100,000–1,000,000 copies/mL.
Lastly, it has been shown that the L74V and M184V muta-
tions confer hypersusceptibility to ZDV [16,17]. However,
in the 338 data set only 5 of the 47 children randomized
to ZDV/3TC/RTV for whom we have data, had the 74V
mutation. This could, however, be an explanation for why
children on the ZDV/3TC/RTV arm who had more base-
line NRTI mutations were more likely to have a viral load
<400 copies/mL at 12 weeks than those with fewer muta-
tions.
Limitations of our study include the fact that we have
baseline resistance data on only a subset of children from
the entire study and lack of information on adherence to
Association between the number of baseline nucleoside reverse transcriptase inhibitor mutations and viral load after 12 weeks on HAART (Viral load is the log10 RNA copies/mL value at 12 weeks.)Figure 1
Association between the number of baseline nucleoside reverse transcriptase inhibitor mutations and viral load after 12 weeks 
on HAART (Viral load is the log10 RNA copies/mL value at 12 weeks.)Page 4 of 8
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bility of the viruses. We did not determine the occurrence
of new resistance mutations after the initiation of HAART
or investigate the virologic impact of these subsequent
resistance mutations.
Conclusion
Despite considerable baseline NRTI resistance, the chil-
dren in PACTG 338 who were treated with a brand new
class of drugs (e.g. ritonavir, the protease inhibitor) in
combination therapy responded favorably and rapidly.
We did not observe an increase in the rate of viral failure
after HAART linked to the presence of resistance muta-
tions at baseline. In fact, viral loads at the 12 week time
point were inversely correlated with the number of base-
line NRTI mutations. It is important to remember that
resistance is not an all-or-none phenomenon, and treat-
ment failure is not defined by a resistance test. In order to
better understand both the virology of mutated viruses in
vivo and their response to anti-retroviral drugs as well as
the use of resistance testing, prospective randomized clin-
ical trials linked with pathogenesis-related in vitro analy-
sis should be performed in children.
Methods
Patient population
PACTG 338 was a multicenter, randomized clinical trial
that enrolled 297 children aged 2–17 years. All subjects
were HIV-infected, had been receiving continuous,
unchanged antiretroviral therapy for the 16 weeks before
study entry, and were naïve to protease inhibitors and
lamivudine (3TC) or had received no more than 6 weeks
of ZDV plus 3TC in the year prior to study entry and none
in the 4 months prior to study entry. Children were ran-
domly assigned to receive either ZDV/3TC (n = 100), sta-
vudine (d4T)/RTV (n = 97) or ZDV/3TC/RTV (n = 100).
Children initially assigned to the ZDV/3TC regimen were
not included in this evaluation of drug resistance and sub-
sequent viral failure as this regimen was demonstrated to
result in a suboptimal virologic suppression compared to
protease inhibitor-based regimens.
A total of 92 children assigned to a RTV-containing regi-
men had both baseline resistance information and viral
load measurement at week 12, and they were included in
any analysis involving the primary endpoint of viral fail-
ure at week 12. Of these 92 subjects, the median age was
7.3 years, median CD4 cell count was 602 cells/mm3, pro-
portion with CD4 cell count <500 cells/uL was 29%, pro-
portion with CD4 percent <25% was 38%, median
plasma HIV-1 RNA was 20,500 copies/mL, and the pro-
portion with HIV-1 RNA copy number > 4 log10 was 75%.
The majority of the children were African-American
(66%) and 51% were male. Children had received prior
treatment with ZDV monotherapy (46%), the combina-
tion of ZDV and ddI (37%) or other combination therapy
(15%). Baseline characteristics of the children in this
resistance analysis were very similar to the baseline char-
acteristics for the overall PACTG 338 study of 297 chil-
dren, except for minor differences in the CD4 cell count
(648 cells/mm3), the proportion of African-American
children (51%), and the proportion with HIV-1 RNA copy
number > 4 log10 (64%). Children with viral loads <1,000
copies/mL were excluded from this resistance study. For
the secondary analyses of viral suppression at weeks 12 or
24 and viral rebound after 48 weeks on HAART, two addi-
tional subjects were included, who did not have viral load
measured at week 12 but did have information at week
24. The institutional review board at each institution
approved the study and informed consent was obtained
from all patients or their guardians.
HIV-1 genotyping
Sequencing was determined in batch at the conclusion of
the study in two laboratories that participated in the
National Institute of Allergy and Infectious Diseases
(NIAID) Virology Quality Assurance Program. For HIV-1
sequencing, plasma RNA was extracted using the QIAam-
Table 2: Association of the level of baseline ZDV resistance mutations and viral failure after 12 weeks on HAART
d4T plus RTV group ZDV plus 3TC plus RTV group
Level of baseline ZDV 
resistance mutation
RNA > 400 at week 12
(N = 19)
RNA ≤ 400 at week 12
(N = 26)
RNA > 400 at week 12
(N = 22)
RNA ≤ 400 at week 12
(N = 25)
Higha 14 19 9 19
Intermediateb 0 0 0 0
Lowc 1 3 4 2
None 4 4 9 4
P-valued 0.904 0.017
a. At least codon 215.
b. At least one of codons 41 and 210, but no high level mutation (none at codon 215).
c. At least one of codons 67, 70 and 219, but no high or intermediate level mutations (none at codons 215, 41 or 210).
d. Mantel-Haenszel test for trend.Page 5 of 8
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transcriptase polymerase chain reaction (RT-PCR) and
direct DNA sequencing of protease and reverse tran-
scriptase genes were performed using the TruGene HIV-1
Genotyping Kit (Visible Genetics-Bayer Diagnostics,
Toronto, Canada) according to the manufacturer's
instructions. The International AIDS Society-USA recom-
mended guidelines for resistance to protease inhibitor
(PI) and nucleoside reverse transcriptase inhibitors
(NRTI) were used [18,19].
Viral load
HIV-1 RNA copy number was assessed using the Nucli-
Sens Assay (Organon Teknika, Durham, NC) [20], which
has a lower limit of quantification of 400 copies/mL. All
RNA assays were performed at a single laboratory at the
University of North Carolina, Chapel Hill, NC that was
certified as proficient by the NIAID Virology Quality
Assurance Program [21]. Assay results from the NucliSens
Assay were adjusted using Virology Quality Assurance
external standards [22].
Statistical analysis
Fisher's exact test was used for associations between spe-
cific baseline resistance mutations and viral failure, the
Kruskal-Wallis test was used to assess the association
between the number of resistance mutations and viral fail-
ure, and the Mantel-Haenszel test for trend was used to
evaluate the association between level of baseline ZDV
resistance and viral failure defined as viral load > 400 cp/
ml [23,24]. Further, the Kruskal-Wallis test was used to
correlate specific baseline resistance mutations and viral
suppression, Fisher's exact test was used to investigate the
association of baseline mutations and viral rebound, and
the association between the total number of resistance
mutations and viral load was assessed using the locally
weighted scatter plot smooth [25] and linear regression
with adjustment for left censoring. All P values were two-
sided and were not adjusted for multiple comparisons.
Because 39 codon sites were evaluated in this analysis,
caution should be exercised in the interpretation of the P
values. A conservative solution to the multiple compari-
sons problem is the Bonferroni method that multiplies
the nominal P value times the overall number of statistical
tests [26]. If the result is still <0.05, then the result is
clearly statistically significant. Using the Bonferroni
approach for any analysis involving individual resistance
codons, a P value between 0.0013 (0.05/39) and 0.05
should be interpreted as suggestive but not necessarily
definitive. P < 0.0013 should be considered clear evidence
of statistical significance.
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